Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In the current tech-heavy market, I explore two compelling value stocks with strong yields and trade at deep discounts to historical valuations. Both have competitive advantages and strong histories of capital returns to shareholders. Both appear to be severely mispriced, offering enterprising investors the opportunity to capture value before the market pendulum swings back.
MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.
Merck & Co., Inc. (NYSE:MRK ) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Caroline A. Litchfield - Executive VP & CFO Dean Y.
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merck's stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.
Merck (MRK) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $2.28 per share a year ago.
Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, as it looks to redirect resources toward new product launches.
Merck (NYSE:MRK) is set to reveal its earnings on Tuesday, July 29, 2025. Historically, MRK stock has exhibited a trend of negative one-day returns following earnings announcements.
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.